NCT00674453View on ClinicalTrials.gov

The Prevention Of Postmenopausal Osteoporosis With Lasofoxifene And Cytokine Evaluation

PHASE2CompletedINTERVENTIONAL
Enrollment

51

Participants

Timeline

Start Date

September 30, 2004

Study Completion Date

September 30, 2007

Conditions
Bone Loss
Interventions
DRUG

Lasofoxifene

Oral tablet, 0.25 mg, daily, 2 years

OTHER

Placebo

Matching placebo tablet given once daily for 2 years

Trial Locations (1)

S5 7AU

Pfizer Investigational Site, Sheffield

Sponsors
All Listed Sponsors
lead

Ligand Pharmaceuticals

INDUSTRY